Matches in Wikidata for { <http://www.wikidata.org/entity/Q91903901> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q91903901 description "artículu científicu espublizáu en mayu de 2019" @default.
- Q91903901 description "im Mai 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91903901 description "scientific article published on 09 May 2019" @default.
- Q91903901 description "wetenschappelijk artikel" @default.
- Q91903901 description "наукова стаття, опублікована 9 травня 2019" @default.
- Q91903901 name "Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa" @default.
- Q91903901 name "Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa" @default.
- Q91903901 type Item @default.
- Q91903901 label "Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa" @default.
- Q91903901 label "Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa" @default.
- Q91903901 prefLabel "Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa" @default.
- Q91903901 prefLabel "Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa" @default.
- Q91903901 P1433 Q91903901-6FB57A06-C3D5-49C9-AB55-171B4FFF4D92 @default.
- Q91903901 P1476 Q91903901-28EBD682-AE79-4730-AB56-70C884749690 @default.
- Q91903901 P2093 Q91903901-46510F7C-1336-4EAC-8A9B-34DE832F8470 @default.
- Q91903901 P2093 Q91903901-82ACFE7B-1EB2-4340-BB0B-084A1135DC5C @default.
- Q91903901 P2093 Q91903901-D3FC1FE4-93F0-444C-A4E5-7DF569DC3C2B @default.
- Q91903901 P2093 Q91903901-D705DBD1-C305-46D8-9715-D8CAC91FDC9E @default.
- Q91903901 P2093 Q91903901-F256D875-98C5-46AC-8BA1-99E53E10EB5F @default.
- Q91903901 P304 Q91903901-E200392E-8A90-42A8-959B-9EC25EB8B67E @default.
- Q91903901 P31 Q91903901-889E98CB-866C-459E-870F-BF39F65897A5 @default.
- Q91903901 P356 Q91903901-44AA5748-93D1-42B6-B29E-248B05EFDEE6 @default.
- Q91903901 P433 Q91903901-534FEFFB-CBF1-457D-A0F8-7DCAA892035F @default.
- Q91903901 P478 Q91903901-13B347D9-605A-4111-8D77-6F11372E0AAA @default.
- Q91903901 P50 Q91903901-0035CE7F-699C-48AB-B85C-B4CACB5911F4 @default.
- Q91903901 P50 Q91903901-A8DB3E57-F11F-47D5-BF3E-F171679547BE @default.
- Q91903901 P577 Q91903901-BF19CCE7-2687-464E-AD4C-D88EEB84405A @default.
- Q91903901 P698 Q91903901-BDF30AE4-E98E-46FC-9EBF-DE99A5796C5E @default.
- Q91903901 P921 Q91903901-8431E327-8975-4435-A35A-EDCDFBC33611 @default.
- Q91903901 P356 S10096-019-03573-4 @default.
- Q91903901 P698 31073653 @default.
- Q91903901 P1433 Q15754378 @default.
- Q91903901 P1476 "Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa" @default.
- Q91903901 P2093 "Grégoire Petitjean" @default.
- Q91903901 P2093 "Matthieu Lafaurie" @default.
- Q91903901 P2093 "Najoua El Helali" @default.
- Q91903901 P2093 "Philippe Lesprit" @default.
- Q91903901 P2093 "on behalf the ATB PK/PD study group" @default.
- Q91903901 P304 "1457-1461" @default.
- Q91903901 P31 Q13442814 @default.
- Q91903901 P356 "10.1007/S10096-019-03573-4" @default.
- Q91903901 P433 "8" @default.
- Q91903901 P478 "38" @default.
- Q91903901 P50 Q56459011 @default.
- Q91903901 P50 Q90506662 @default.
- Q91903901 P577 "2019-05-09T00:00:00Z" @default.
- Q91903901 P698 "31073653" @default.
- Q91903901 P921 Q31856 @default.